desktop version →
Lengua & la divisa
Cesta 0 Productos $0.00
Envío gratis
sobre todos los pedidos superiores $200
Píldoras libres
con cado pedido
1,000,000 clientes
Calidad, privacidad, Seguridad
Precios bajos
el mejor precio del web
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Productos

Anti Viral - Lagevrio (Brand name: movfor)

Movfor
Molnupiravir, an Oral Antiviral Treatment for COVID-19
Ingrediente activo: Molnupiravir
Disposición: Disponible (14 empacadores)
Ahorre su dinero
Grandes descuentos por los paquetes grandes
Movfor 200mg
Nombre del productoPor píldoraAhorro (solo hoy)Por paquete
40 tapas$7.40$296.00COMPRAR
80 tapas$6.24$92.50$592.00 $499.50COMPRAR
120 tapas$5.86$185.00$888.00 $703.00COMPRAR
160 tapas$5.67$277.50$1184.00 $906.50COMPRAR
200 tapas$5.55$370.00$1480.00 $1110.00COMPRAR
  • Background

    Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19.

    Methods

    Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days. Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.

    Results

    Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.

    Conclusions

    Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.

mobile version →